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Abstract
Since every single test has some limitations for detecting toxigenic Clostridium difficile, mul-
tistep algorithms are recommended. This study aimed to compare the current, representa-
tive diagnostic algorithms for detecting toxigenic C. difficile, using VIDAS C. difficile toxin
A&B (toxin ELFA), VIDAS C. difficileGDH (GDH ELFA, bioMérieux, Marcy-l’Etoile, France),
and Xpert C. difficile (Cepheid, Sunnyvale, California, USA). In 271 consecutive stool sam-
ples, toxigenic culture, toxin ELFA, GDH ELFA, and Xpert C. difficile were performed. We
simulated two algorithms: screening by GDH ELFA and confirmation by Xpert C. difficile
(GDH + Xpert) and combined algorithm of GDH ELFA, toxin ELFA, and Xpert C. difficile
(GDH + Toxin + Xpert). The performance of each assay and algorithm was assessed. The
agreement of Xpert C. difficile and two algorithms (GDH + Xpert and GDH+ Toxin + Xpert)
with toxigenic culture were strong (Kappa, 0.848, 0.857, and 0.868, respectively). The sen-
sitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of
algorithms (GDH + Xpert and GDH + Toxin + Xpert) were 96.7%, 95.8%, 85.0%, 98.1%,
and 94.5%, 95.8%, 82.3%, 98.5%, respectively. There were no significant differences
between Xpert C. difficile and two algorithms in sensitivity, specificity, PPV and NPV. The
performances of both algorithms for detecting toxigenic C. difficile were comparable to that
of Xpert C. difficile. Either algorithm would be useful in clinical laboratories and can be opti-
mized in the diagnostic workflow of C. difficile depending on costs, test volume, and clinical
needs.
Introduction
Clostridium difficile is a primary pathogen causing antibiotic-associated colitis and responsible for
15–25% of cases of nosocomial antibiotic-associated diarrhea [1, 2]. The clinical manifestations of
C. difficile infection (CDI) range frommild diarrhea to pseudomembranous colitis and cannot be
distinguished with those from other causes, making laboratory confirmation essential [1, 3].
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The two reference methods for detecting toxigenic C. difficile are the toxigenic culture and
cell cytotoxicity assay [4, 5]. However, these assays have limitations such as long turnaround
time, technical complexity, and lack of standardization [6]. In practice, the most widely used
technique for detecting toxigenic C. difficile had been toxin detection using enzyme immunoas-
say (EIA). It is fast and inexpensive; however, its low sensitivity is a limitation for its use [7, 8].
Glutamate dehydrogenase (GDH) is a common antigen of the C. difficile cell wall and GDH
testing detects both non-toxigenic and toxigenic C. difficile. It shows high sensitivity and negative
predictive value (NPV), but it should be paired with a test detecting toxin [1, 9]. Recently, nucleic
acid amplification testing (NAAT), including rapid, ready-to-use molecular assays, has been
introduced and shown high sensitivity and specificity [9–11]. However, its cost-effectiveness as
well as its usefulness as a stand-alone test is still questionable [1, 4, 9–13]. Since every single test
has some limitations, many experts and guidelines recommend the approaches using multiple
tests (multistep algorithms) for the detection of toxigenic C. difficile [1, 9, 11, 13–15].
This study aimed to compare the current, representative diagnostic algorithms for detecting
toxigenic C. difficile, using VIDAS C. difficile toxin A&B, VIDAS C. difficile GDH (bioMérieux,
Marcy-l’Etoile, France), and Xpert C. difficile (Cepheid, Sunnyvale, California, USA).
Materials and Methods
Clinical samples
This in vitro study was approved by the Institutional Review Board of the Konkuk University
Medical Center, Seoul, Korea (a tertiary referral hospital with 900 beds). From January 2015 to
April 2015, we collected 271 consecutive, remnant diarrheal stool samples submitted to the
clinical microbiology laboratory from patients admitted to our hospital.They included 258
adults and 13 children (male 148, female 123). Since we used remnant samples after routine
tests and the data were analyzed anonymously, informed consent was exempted. As a routine
practice of C. difficile testing in our hospital, we performed toxigenic culture and VIDAS C. dif-
ficile toxin A&B (bioMérieux) simultaneously. The VIDAS C. difficile GDH (bioMérieux) and
Xpert C. difficile (Cepheid) were additionally performed in the same samples. Duplicated sam-
ples from the same patients and from patients on treatment for CDI were excluded. The sam-
ples were tested within 2 hours of collection; otherwise, they were kept at 2–8°C for up to 2
days.
Toxigenic culture of C. difficile
The alcohol-shocked stool samples were inoculated onto on a chromogenic agar plate (chro-
mID CD agar, bioMérieux), and the plates were incubated at 37°C under anaerobic conditions
(Forma Anaerobic System; Thermo Fisher Scientific, Waltham, MA, USA) for 48 hrs. The iso-
lates of typical morphology with gray-to-black colonies with irregular or smooth borders suspi-
cious for C. difficile were initially investigated by Gram staining and finally identified by the
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) using VITEKMS sys-
tem (bioMérieux). Isolates of C. difficile were examined for toxin production using in-house
PCR as described previously [16, 17].
VIDAS C. difficile toxin A&B and VIDAS C. difficileGDH
Stool samples were tested for toxin and GDH using VIDAS C. difficile toxin A&B and VIDAS
C. difficile GDH kit (bioMérieux), respectively, according to the manufacturer's instructions.
The assay principle combines a two-step enzyme immunoassay sandwich method with a final
fluorescent detection (enzyme-linked fluorescence immunoassay, ELFA). An aliquot of liquid
Diagnostic Algorithms for ToxigenicC. difficile
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stool was added in the specific diluent, and supernatant after centrifugation was tested. The
VIDAS C. difficile toxin A&B is completed within 75 minutes, and results are reported as nega-
tive, equivocal, or positive with cut-offs of 0.13 and 0.37 test value (TV). There were 10 equivo-
cal results in our study and they were considered negative for the performance calculations in
this study. The VIDAS C. difficile GDH is completed within 50 minutes, and results are
reported as negative or positive with a cut-off of 0.10 of TV.
Xpert C. difficile
Xpert C. difficile system(Cepheid) is an automated, real-time multiplex PCR assay using dis-
posable cartridge. This assay detects toxin B (tcdB), binary toxin (cdt), and a point mutation
associated with PCR ribotype 027. The result of the toxin B target means the presence of toxi-
genic C. difficile. The results of other targets indicate additional information regarding ribotype
027. The invalid result is reported when sample processing control is failed, indicating that the
sample is not properly processed or PCR is inhibited. Using a maximum valid cycle threshold
setting of 37 for tcdB, the limit of detection point estimate for toxigenic C. difficile is 1,657
CFU/swab (95% confidence interval [CI], 1,157–3,561 CFU/swab), according to the manufac-
turer’s insert.
Diagnostic algorithms
We selected the following diagnostic algorithms using VIDAS C. difficile toxin A&B (toxin
ELFA), VIDAS C. difficile GDH (GDH ELFA), and Xpert C. difficile (Fig 1); GDH-based
2-step algorithm, in which GDH ELFA is initially performed and followed by toxin gene detec-
tion using Xpert C. difficile (GDH + Xpert)[11] and combined algorithm of GDH ELFA, toxin
ELFA, and Xpert C. difficile, in which the initial screening is performed with GDH ELFA and
toxin ELFA simultaneously and followed by Xpert C. difficile in discordant samples (GDH
+ Toxin + Xpert)[9]. The average costs and assay times were simulated based on generally used
reagent costs [18, 19] and assay times shown in insert papers of individual assays.
Statistical analysis
The sensitivity, specificity, positive predictive values (PPV),and NPV with 95% CI of each
assay and algorithm were determined based on the results of toxigenic culture as a gold stan-
dard. McNemar’s test was used for the statistical differences of sensitivity and specificity
between assays and algorithms and chi-square test for the statistical differences of PPV and
NPV between them. Agreement between assays were determined using Cohen’s Kappa (agree-
ment:< 0.20, none; 0.21–0.39, minimal; 0.40–0.59, weak; 0.60–0.79, moderate; 0.80–0.90,
strong;> 0.90, almost perfect) [20]. Statistical analysis was performed using MedCalc Statisti-
cal Software (version 12.3.0, MedCalc Software, Mariakerke, Belgium) and IBM SPSS Statistics
22.0 (IBM Corporation, Armonk, NY, USA).
Results
The result of each assay and algorithm was compared with that of toxigenic culture (Table 1).
The agreement of toxin ELFA and GDH ELFA with toxigenic culture were weak and moderate
(Kappa, 0.564 and 0.678, respectively). The agreement of the Xpert C. difficile and the two algo-
rithms (GDH + Xpert and GDH + Toxin + Xpert) with toxigenic culture were strong (Kappa,
0.848, 0.857, and 0.868, respectively).
Based on toxigenic culture, toxin ELFA showed significantly lower sensitivity and NPV
than the other assays and algorithms (P< 0.0001, both), while GDH ELFA showed
Diagnostic Algorithms for ToxigenicC. difficile
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significantly lower specificity (P< 0.0001) and PPV (P = 0.0113, 0.0079, 0.0030 and 0.0094,
respectively) than toxin GDH, Xpert C. difficile, GDH + Xpert, and GDH + Toxin + Xpert
(Table 2). There were no significant differences between the Xpert C. difficile, GDH + Xpert,
and GDH + Toxin + Xpert in sensitivity, specificity, PPV, and NPV. Their sensitivity and spec-
ificity ranged from 95% to 97%. Their PPV ranged from 82% to 85%, and their NPV were all
above 98%.
Fig 1 shows the distribution of samples in each step of algorithms. The proportion of sam-
ples reported at the first step of algorithm was 68.6% (186/271) by GDH + Xpert and 78.6%
(213/271) by GDH + Toxin + Xpert (Fig 1 and Table 3). Based on our distribution of samples,
estimated average costs and assay times are also shown in Table 3. Cost per sample included
reagent costs only and other costs like labor or quality control were not included. The assay
time is calculated when GDH and toxin assays are performed concurrently in separate racks.
The assay time per 30 samples was simulated based on capacity of our laboratory which has 1
GeneXpert with 4 cartilages spaces and 1 VIDAS with 5 racks (30 samples load).
Fig 1. The diagnostic algorithms and distribution of samples in each step of algorithms.GDH-based 2-step algorithm, in which GDH ELFA is initially
performed and followed by toxin gene detection using the Xpert C. difficile (GDH + Xpert) (left) and combined algorithm of toxin ELFA, GDH ELFA and the
XpertC. difficile, in which initial screening is performed with GDH ELFA and toxin ELFA simultaneously and followed by the XpertC. difficile in discordant
samples (GDH + Toxin + Xpert) (right). One invalid result by the Xpert C. difficile is included.
doi:10.1371/journal.pone.0161139.g001
Table 1. Comparison of each assay and algorithm with toxigenic culture.
Toxigenic culture Toxin ELFA GDH ELFA Xpert C. difﬁcile GDH + Xpert GDH + Toxin + Xpert
Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative
Positive 27 28 53 2 52 3 51 4 52 3
Negative 4 212 32 184 11 204 9 206 9 206
Total 31 240 85 186 63 207 60 210 61 209
Kappa 0.564 0.678 0.848 0.856 0.868
95% CI 0.433–0.695 0.581–0.775 0.772–0.925 0.781–0.932 0.796–0.941
doi:10.1371/journal.pone.0161139.t001
Diagnostic Algorithms for ToxigenicC. difficile
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Discussion
The best laboratory method for diagnosis of CDI remains controversial. The widely used assays
have been C difficile toxin EIA, GDH EIA, and NAAT, and they have different targets. The
toxin EIA directly detects free toxin in feces, GDH test detects a common antigen produced by
C difficile, and NAAT detects toxin genes but not free toxin [4, 21]. Although the commercially
available toxin and GDH EIA are simple, rapid, and inexpensive, they are not suitable as stand-
alone tests due to suboptimal sensitivity and specificity, respectively [1, 15]. Accordingly, sev-
eral two- or three-step algorithms have been proposed, and more various algorithms are now
in use in routine laboratories [1, 4, 9, 11, 13–15]. We wanted to compare the representative
diagnostic algorithms for detecting toxigenic C. difficile using updated, automated, and widely
used assays in clinical samples. Compared with toxigenic culture, two diagnostic algorithms,
GDH + Xpert and GDH + Toxin + Xpert, showed strong agreements that are comparable to
that of the Xpert C. difficile (Table 1).
In this study, toxin ELFA showed significantly lower sensitivity (49.1%) and NPV (88.3%)
with comparable specificity and PPV to the other assays and algorithms. This finding is gener-
ally in line with most previous reports. Toxin EIA including ELFA, however, have shown
widely varying sensitivity (32–99%) and specificity (65–100%), depending types of assays and
used reference methods [1, 9]. Although toxin EIA or toxin PCR after GDH assay had been rec-
ommended in early guidelines [14], the algorithm screening by GDH ELFA confirmed by
toxin ELFA also showed low sensitivity (sensitivity 47.3%, CI, 33.9–61.2 and specificity 98.6%,
CI, 95.7–99.6, data not shown) similar to that of toxin ELFA only. There is equivocal zone in
toxin ELFA and there were 10 equivocal results in our study. Among them, 4 samples were
Table 2. Overall performance of each assay and algorithm based on toxigenic culture.
Toxin ELFA GDH ELFA Xpert C. difﬁcile GDH+ Xpert GDH+Toxin+ Xpert
Sensitivity 49.1% 96.4% 94.6% 96.7% 94.5%
95% CI (35.4% - 62.9%) (87.5% - 99.6%) (84.9% - 98.8%) (82.4% - 97.9%) (84.8% - 98.9%)
Speciﬁcity 98.2% 85.2% 94.9 95.8% 95.8%
95% CI (95.3% - 99.5%) (79.7% - 89.6%) (91.0% - 97.4%) (92.2% - 98.1%) (92.2% - 98.1%)
PPV 87.1% 62.4% 82.5% 85.0% 82.3%
95% CI (70.2% - 96.4%) (51.2% - 72.6%) (70.9% - 90.9%) (73.4% - 92.9%) (73.8% - 93.2%)
NPV 88.3% 98.2% 98.6% 98.1% 98.5%
95% CI (83.6% - 92.4%) (96.2% - 99.9%) (95.8% - 99.7%) (95.2% - 99.5%) (95.9% - 99.7%)
doi:10.1371/journal.pone.0161139.t002
Table 3. The reagent costs and assay times of the two diagnostic algorithms of C. difficile compared with those of XpertC. difficile.
Samples reported, n. (%) Cost per sample, USD Assay time per sample Assay time per 30 samples
Samples N. of runs Time
GDH + Xpert
1 step 186 (68.6%) 10 50 min 30 1 50 min
2 step 85 (31.4%) 10 + 50 50 + 45 min 9 3 135 min
Average 25.7 64.1 min Total 185 min
GDH + Toxin + Xpert
1 step 213 (78.6%) 20 75 min 30 2 100 min
2 step 58 (21.4%) 20 + 50 75 + 45 min 6 2 90 min
Average 30.7 84.6 min Total 190 min
Xpert C. difﬁcile only
1 step 271 (100.0%) 50 45 min 30 8 360 min
doi:10.1371/journal.pone.0161139.t003
Diagnostic Algorithms for ToxigenicC. difficile
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toxigenic culture positive and 5 samples were Xpert C. difficile positive. When we considered
equivocal results as positive category, toxin ELFA showed higher sensitivity and lower specific-
ity (56.4%, CI, 42.4–69.5 and 95.4%, CI, 91.4–97.6, respectively) but they were not significant.
Most previous studies on GDH tests used ELISA kits [9]. Only a few, recent studies evalu-
ated GDH ELFA, and GDH ELFA showed high sensitivity and NPV comparable to those of
the Xpert C. difficile, suggesting that it is suitable for initial screening [22–24].
Our study demonstrated the high sensitivities and specificities of the Xpert C. difficile and
both algorithms (GDH + Xpert and GDH + Toxin + Xpert). The performance of the Xpert C.
difficile was comparable to those of recent reports (sensitivity, 94.4–100.0%; specificities, 93.0–
98.8%) [18, 25, 26]. There was no significant difference in sensitivity, specificity, PPV, and
NPV between the Xpert C. difficile and each algorithm. This finding demonstrates that we can
choose either one in terms of performance (Table 2).
Regarding the costs, 68.6% of samples by GDH + Xpert and 78.6% by GDH + Toxin
+ Xpert had the cost per sample of $10 and $20, respectively, and the other samples submitted
to the second step had higher cost per sample of $60 and $70, respectively (Table 3). The cost
of Xpert C. difficile was about $50 per sample. Based on the distribution of our samples, the
average cost per sample in the two algorithms was estimated to be $25.7 and $30.7, respectively;
it was lower than that of the Xpert C. difficile. However, rapid detection of CDI by Xpert C. dif-
ficilemay offset laboratory costs by reducing hospitalization and C. difficile transmission from
the view of total medical costs [27].
In terms of assay time excluding preparation step, the Xpert C. difficile could report the
results of each sample within an hour. The GDH + Xpert and GDH + Toxin + Xpert algo-
rithms could report 68.6% and 78.6% of samples, within 50 min and 75 min, respectively; it
was comparable to the Xpert C. difficile. For the other samples submitted to the second step, it
took about twice of time. Comparing the two algorithms, GDH + Xpert had shorter assay time
and sample cost, but GDH + Toxin + Xpert could report more samples at the first step.
The actual cost and turnaround time can vary across laboratories, according to the work-
flow, the number of requested tests, and many other factors. The Xpert C. difficile can be per-
formed immediately on demand or several times per day according to the number of spaces for
cartilages in instrument. For examples, simulated assay time per 30 samples (maximal daily
number of requested tests in our hospital) would be extended in Xpert C. difficile when number
of space for cartilages in GeneXpert system is limited, 4 cartilages in our system (Table 3). The
system with more cartilages loading is needed for rapid reporting. The VIDAS system for GDH
ELFA and toxin ELFA is also simple and easy to perform, offering routine batch or random
access testing, whereas conventional ELISA system is difficult to perform as random access
testing. Each laboratory can determine its own policy and can optimize the diagnostic work-
flow depending on its situations.
In this study, we evaluated the performances of assays and algorithms based on toxigenic
culture as a reference standard, which is suggested by many experts and guidelines [1, 9].
Another reference standard is the cell cytotoxicity assay, and these two reference methods have
different targets, toxigenic C. difficile isolates and direct toxin, respectively [4, 5]. A recent, mul-
ticenter study showed that toxin positivity by cytotoxicity assay more correlated with clinical
outcomes, and toxigenic culture could detect the C. difficile excretes with diarrhea not due to
CDI [4]. It also showed that GDH + NAAT and toxin EIA + NAAT best reproduced toxigenic
culture and cell cytotoxin assay, respectively. Moreover, NAAT itself and confirmation by
NAAT in the second step of algorithms could overdiagnose CDI [4, 9, 11]. Since toxin detec-
tion is still important and has a clinical impact, toxin assays with improved performances are
expected. In addition to the detection itself, performances of assays and algorithms need to be
evaluated along with their clinical significances in further studies.
Diagnostic Algorithms for ToxigenicC. difficile
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In conclusion, both algorithms screening with GDH and/or toxin ELFA confirmed by the
Xpert C. difficile showed comparable performances to that of the Xpert C. difficile. This data
would be helpful to choose the diagnostic algorithms for the detection of CDI in clinical labora-
tories. Each laboratory can optimize its diagnostic workflow in accordance with its situation
encompassing the costs, test volumes, and clinical needs.
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